Validation of Population Pharmacokinetic Models for Clozapine Dosage Prediction

Massimo Berneri,Uma Jha,Seán O'Halloran,Sam Salman,Shanek Wickramasinghe,Kevin Kendrick,Jessica Nguyen,David A Joyce,David A. Joyce
DOI: https://doi.org/10.1097/ftd.0000000000001184
2024-03-16
Therapeutic Drug Monitoring
Abstract:Clozapine is unique in its capacity to ameliorate severe schizophrenia but at high risk of toxicity. A relationship between blood concentration and clinical response and evidence for concentration–response relationships to some adverse effects justify therapeutic drug monitoring of clozapine. However, the relationship between drug dose and blood concentration is quite variable. This variability is, in part, due to inductive and inhibitory interactions varying the activity of cytochrome P450 1A2 (CYP1A2), the principal pathway for clozapine elimination. Several population pharmacokinetic models have been presented to facilitate dose selection and to identify poor adherence in individual patients. These models have faced little testing for validity in independent populations or even for persisting validity in the source population.
pharmacology & pharmacy,medical laboratory technology,toxicology
What problem does this paper attempt to address?